A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations

• Κύριοι συγγραφείς: K Gadkar (Συγγραφέας), N Budha (Συγγραφέας), A Baruch (Συγγραφέας), J D Davis (Συγγραφέας), P Fielder (Συγγραφέας), S Ramanujan (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2014-11-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

PCSK9 is a promising target for the treatment of hyperlipidemia and cardiovascular disease. A Quantitative Systems Pharmacology model of the mechanisms of action of statin and anti‐PCSK9 therapies was developed to predict low density lipoprotein (LDL) changes in response to anti‐PCSK9 mAb for differ...